A federal judge ruled Monday that the Obama administration's loosening of federal funds for embryonic stem cell research was illegal. The ruling will be appealed, but in the meantime it throws a blanket of uncertainty over the research community's ability to conduct ESC-related work in settings that might have federally funded staff, equipment or facilities.
Roche/Genentech’s Avastin takes another step forward toward an indication in ovarian cancer with the July 2 release of positive topline results from a second Phase III study showing an undisclosed benefit for progression free survival.
ImmunoGen presents data at the American Society of Clinical Oncology's annual meeting on one of its growing number of internal compounds, IMGN388, in early development against solid tumors. The antibody conjugate company is building on positive results with trastuzumab-DM1, the Herceptin-based hybrid it built for Roche.
The European Court of Justice handed generics firms a victory on Thursday when it ruled that UK doctors could legally be incentivized to prescribe cheaper drugs.
In the first of a two-part interview, “The Pink Sheet” DAILY talks with King Pharmaceuticals CEO Brian Markison and Chief Scientific Officer Eric Carter about the company’s hopes for a wave of new drug formulations to treat chronic pain with lower abuse potential.
Read about why China's State FDA will launch a new fast-track mechanism by year end called the special approval procedure for drug registration to accelerate drug registration...
